Guggenheim Capital LLC Buys 1,411 Shares of Eli Lilly and Company $LLY

by · The Markets Daily

Guggenheim Capital LLC lifted its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 5.9% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 25,431 shares of the company’s stock after buying an additional 1,411 shares during the period. Guggenheim Capital LLC’s holdings in Eli Lilly and Company were worth $19,824,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Raab & Moskowitz Asset Management LLC grew its position in Eli Lilly and Company by 1.4% during the 2nd quarter. Raab & Moskowitz Asset Management LLC now owns 2,023 shares of the company’s stock worth $1,577,000 after acquiring an additional 27 shares during the last quarter. Miramar Capital LLC purchased a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $234,000. Kilter Group LLC bought a new position in shares of Eli Lilly and Company in the second quarter worth approximately $65,000. EverSource Wealth Advisors LLC grew its holdings in shares of Eli Lilly and Company by 21.4% in the second quarter. EverSource Wealth Advisors LLC now owns 6,120 shares of the company’s stock worth $4,771,000 after purchasing an additional 1,078 shares during the last quarter. Finally, Trek Financial LLC raised its holdings in Eli Lilly and Company by 76.2% during the 2nd quarter. Trek Financial LLC now owns 2,181 shares of the company’s stock valued at $1,700,000 after buying an additional 943 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 2.1%

NYSE:LLY opened at $1,011.74 on Friday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm’s 50-day moving average price is $913.15 and its 200-day moving average price is $807.53. The company has a market capitalization of $956.48 billion, a PE ratio of 49.50, a P/E/G ratio of 1.15 and a beta of 0.37. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,111.99.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. Eli Lilly and Company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a $1.50 dividend. The ex-dividend date is Friday, November 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Guggenheim reissued a “buy” rating and issued a $1,163.00 price target on shares of Eli Lilly and Company in a report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Monday. Wolfe Research boosted their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a report on Wednesday. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Finally, Erste Group Bank upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,087.32.

Read Our Latest Research Report on LLY

About Eli Lilly and Company

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

See Also